# Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

> **NCT03711058** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 48 (actual)

## Conditions studied

- Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor
- Microsatellite Stable (MSS) Colon Cancer

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03711058
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2022-06-14
- **Final completion:** 2025-06-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711058, "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT03711058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*